试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-13
Bryophyllum Pinnatum Treatment of Anxiety Related to Signs of Preterm Birth
编号:NCT05110599登记状态:提前终止企业 / 申办者:Christian Haslinger
药物 / 成分:Bryophyllum 50% chewable tablets、Placebo
登记的停止原因(原文):Slow recruitment and expired study medication.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-12
Women With Chest Pain and Normal Coronary Arteries Study
编号:NCT00743197登记状态:提前终止企业 / 申办者:Northwestern University
药物 / 成分:Aspirin、Lisinopril、Simvastatin、Lovaza
登记的停止原因(原文):Terminated due to departure of PI from institution.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-12
DLBS1033 for Acute Ischemic Stroke Patients
编号:NCT02133521登记状态:提前终止企业 / 申办者:Dexa Medica Group
药物 / 成分:DLBS1033、Placebo
登记的停止原因(原文):Very low recruitment rate. The Study Sites classified as tertiary referral hospital. Therefore, patients being referred to the site are mostly those with comorbidities included in the exclusion criteria.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-12
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
编号:NCT02382549登记状态:提前终止企业 / 申办者:Craig L Slingluff, Jr
药物 / 成分:BRAF inhibitor、6MHP、MEK inhibitor
登记的停止原因(原文):The study was terminated because of slow accruals.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-12
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
编号:NCT03525392登记状态:提前终止企业 / 申办者:Ipsen
药物 / 成分:177Lu-3BP-227 (also called 177Lu-IPN01087)
登记的停止原因(原文):Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-12
Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
编号:NCT03552692登记状态:提前终止企业 / 申办者:Fondazione Italiana Linfomi - ETS
药物 / 成分:Venetoclax
登记的停止原因(原文):efficacy lower than expected
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-12
Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers
编号:NCT03654989登记状态:提前终止企业 / 申办者:University Hospital, Grenoble
药物 / 成分:Treprostinil iontophoresis、Remodulin® placebo iontophoresis
登记的停止原因(原文):recruitment difficulties
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-12
Simplified Insulin Regimen for the Elderly
编号:NCT03660553登记状态:提前终止企业 / 申办者:University of Miami
药物 / 成分:Insulin Glargine、Insulin Glargine、Insulin Aspart、Insulin Lispro
登记的停止原因(原文):PI left University of Miami
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-12
Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity
编号:NCT03954990登记状态:提前终止企业 / 申办者:The University of Texas Medical Branch, Galveston
药物 / 成分:Metronidazole Oral、Placebo Oral Tablet
登记的停止原因(原文):Lack of significance/futile study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-12
A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention
编号:NCT04848220登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Temanogrel、Placebo
登记的停止原因(原文):Business decision
查看官方原始记录 ↗